258 related articles for article (PubMed ID: 35659375)
1. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury.
Imig JD
Adv Pharmacol; 2022; 94():27-55. PubMed ID: 35659375
[TBL] [Abstract][Full Text] [Related]
2. Orally Active Epoxyeicosatrienoic Acid Analogs.
Campbell WB; Imig JD; Schmitz JM; Falck JR
J Cardiovasc Pharmacol; 2017 Oct; 70(4):211-224. PubMed ID: 28937442
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic acid analogs and vascular function.
Sudhahar V; Shaw S; Imig JD
Curr Med Chem; 2010; 17(12):1181-90. PubMed ID: 20158473
[TBL] [Abstract][Full Text] [Related]
4. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
Lai J; Chen C
Front Physiol; 2021; 12():642470. PubMed ID: 33716791
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosanoids in hypertension.
Imig JD
Physiol Res; 2019 Oct; 68(5):695-704. PubMed ID: 31475560
[TBL] [Abstract][Full Text] [Related]
6. Inside epoxyeicosatrienoic acids and cardiovascular disease.
Tacconelli S; Patrignani P
Front Pharmacol; 2014; 5():239. PubMed ID: 25426071
[TBL] [Abstract][Full Text] [Related]
7. Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy.
Hye Khan MA; Fish B; Wahl G; Sharma A; Falck JR; Paudyal MP; Moulder JE; Imig JD; Cohen EP
Clin Sci (Lond); 2016 Apr; 130(8):587-99. PubMed ID: 26772189
[TBL] [Abstract][Full Text] [Related]
8. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
9. Role of epoxyeicosatrienoic acids (EETs) in mediation of dopamine's effects in the kidney.
Zhang MZ; Wang Y; Yao B; Gewin L; Wei S; Capdevila JH; Harris RC
Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1680-6. PubMed ID: 24154693
[TBL] [Abstract][Full Text] [Related]
10. Role of the adenosine(2A) receptor-epoxyeicosatrienoic acid pathway in the development of salt-sensitive hypertension.
Carroll MA
Prostaglandins Other Lipid Mediat; 2012 Aug; 98(3-4):39-47. PubMed ID: 22227265
[TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury.
Khan AH; Falck JR; Manthati VL; Campbell WB; Imig JD
Front Pharmacol; 2014; 5():216. PubMed ID: 25295006
[TBL] [Abstract][Full Text] [Related]
12. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity.
Khan MA; Liu J; Kumar G; Skapek SX; Falck JR; Imig JD
FASEB J; 2013 Aug; 27(8):2946-56. PubMed ID: 23603837
[TBL] [Abstract][Full Text] [Related]
13. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
14. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition.
Hye Khan MA; Pavlov TS; Christain SV; Neckář J; Staruschenko A; Gauthier KM; Capdevila JH; Falck JR; Campbell WB; Imig JD
Clin Sci (Lond); 2014 Oct; 127(7):463-74. PubMed ID: 24707975
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
17. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
18. Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity.
Imig JD; Hye Khan MA; Burkhan A; Chen G; Adebesin AM; Falck JR
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33801911
[TBL] [Abstract][Full Text] [Related]
19. 5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.
Pomposiello SI; Quilley J; Carroll MA; Falck JR; McGiff JC
Hypertension; 2003 Oct; 42(4):548-54. PubMed ID: 12939232
[TBL] [Abstract][Full Text] [Related]
20. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions.
Imig JD; Elmarakby A; Nithipatikom K; Wei S; Capdevila JH; Tuniki VR; Sangras B; Anjaiah S; Manthati VL; Sudarshan Reddy D; Falck JR
Front Physiol; 2010; 1():157. PubMed ID: 21423396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
